The DOI matches its OpenAlex record; 23 of the 23 references it cites were found in a registry or an index.
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter
Open accessAbstract
Loss of DNA mismatch repair because of hypermethylation of the hMLH1 gene promoter occurs at a high frequency in a number of human tumors. A role for loss of mismatch repair (MMR) in resistance to a number of clinically important anticancer drugs has been shown. We have investigated whether the demethylating agent 2'-deoxy-5-azacytidine (DAC) can be used in vivo to sensitize MMR-deficient, drug-resistant ovarian (A2780/cp70) and colon (SW48) tumor xenografts that are MLH1 negative because of gene promoter hypermethylation. Treatment of tumor-bearing mice with the demethylating agent DAC at a nontoxic dose induces MLH1 expression. Re-expression of MLH1 is associated with a decrease in hMLH1 gene promoter methylation. DAC treatment alone has no effect on the growth rate of the tumors. However, DAC treatment sensitizes the xenografts to cisplatin, carboplatin, temozolomide, and epirubicin. Sensitization is comparable with that obtained by reintroduction of the hMLH1 gene by chromosome 3 transfer. Consistent with loss of MMR having no effect on sensitivity in vitro to Taxol, DAC treatment has no effect on the Taxol sensitivity of the xenografts. DAC treatment does not sensitize xenografts of HCT116, which lacks MMR because of hMLH1 mutation. Because there is emerging data on the role of loss of MMR in clinical drug resistance, DAC could have a role in increasing the efficacy of chemotherapy for patients whose tumors lack MLH1 expression because of hMLH1 promoter methylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,344
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J.-P. J., Markowitz, S., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
Jüttermann, R., Li, E., & Jaenisch, R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.11797 · Cited by 678
How does DNA methylation repress transcription?
Kass, S. U., Pruss, D., & Wolffe, A. P. (1997) · Trends in Genetics · doi:10.1016/s0168-9525(97)01268-7 · Cited by 535
The role of DNA mismatch repair in drug resistance.
Fink, D. A., Aebi, S. P., & Howell, S. B. (1998) · PubMed · Cited by 410
Bender, C. M., Pao, M. M., & Jones, P. A. (1998) · PubMed · Cited by 380
Leung, S. Y., Yuen, S. T., Chung, L.-P., Chu, K., Chan, A. S. Y., & Ho, J. C. I. (1999) · PubMed · Cited by 365
Strathdee, G., MacKean, M. J., Illand, M., & Brown, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202540 · Cited by 350
Self-citationDependence of transcriptional repression on CpG methylation density.
Hsieh, C. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5487 · Cited by 300
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., & Anthoney, D. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201167 · Cited by 243
Self-citationCauses and consequences of microsatellite instability in endometrial carcinoma.
Gurin, C. C., Federici, M. G., Kang, L., & Boyd, J. A. (1999) · PubMed · Cited by 215
Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
Anthoney, A., McIlwrath, A. J., Gallagher, W. M., Edlin, A., & Brown, R. E. (1996) · PubMed · Cited by 210
Self-citationMomparler, R. L., Bouffard, D. Y., Momparler, L. F., Dionne, J., B??langer, K., & Ayoub, J. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199704000-00008 · Cited by 210
In Vitro Reactivation of the FMR1 Gene Involved in Fragile X Syndrome
Chiurazzi, P., Pomponi, M. G., Willemsen, R., Oostra, B. A., & Neri, G. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.1.109 · Cited by 198
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Aebi, S. P., Fink, D. A., Gordon, R., Kim, H. K. W., Zheng, H., Fink, J. L., & Howell, S. B. (1997) · PubMed · Cited by 180
hMutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage
Duckett, D. R., Bronstein, S. M., Taya, Y., & Modrich, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12384 · Cited by 178
Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine
Toft, N. J., Winton, D. J., Kelly, J., Howard, L. A., Dekker, M., te Riele, H., Arends, M. J., Wyllie, A. H., Margison, G. P., & Clarke, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3911 · Cited by 168
Wheeler, J., Beck, N. E., Kim, H. C., Tomlinson, I. P. M., Mortensen, N. J. M., & Bodmer, W. F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10296 · Cited by 119
Durant, S. T., Morris, M. M., Illand, M., McKay, H. J., McCormick, C., Hirst, G. L., Borts, R. H., & Brown, R. E. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80047-5 · Cited by 100
Self-citationMomparler, R. L., Côté, S., & Eliopoulos, N. (1997) · Leukemia · doi:10.1038/sj.leu.2400550 · Cited by 70
Buermeyer, A. B., Patten, C. W.-V., Baker, S. M., & Liskay, R. M. (1999) · PubMed · Cited by 68
Carcinogenicity and haemoglobin synthesis induction by cytidine analogues
Carr, B. I., Rahbar, S., Asmeron, Y., Riggs, A. D., & Winberg, C. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.89 · Cited by 49
Cited by
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Metadata
- Authors
- Plumb, J. A., Strathdee, G. R., Sludden, J., Kaye, S. B., & Brown, R. E.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2000-12-31
- Volume
- 60
- Issue
- 21
- Pages
- 6039-44
- OpenAlex
- W1546270188
- Cited by
- 486
- References
- 23
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.